A restriction fragment length polymorphism assay that differentiates human N-acetyltransferase-1 (NAT1) alleles.
Currently there is much interest in the N-acetyltransferase-1 (NAT1) genetic polymorphism and its relationship to cancer. Previous studies have described methods to distinguish NAT1 alleles through polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP) and/or allele-specific amplification. However, these methods detect at most only four of the NAT1 alleles identified in human populations. In this paper we describe a PCR-RFLP-based assay that differentiates among eight human NAT1 alleles (NAT1*3, *4, *5, *10, *11, *14, *15, *16). This method should prove useful in molecular epidemiological studies investigating associations between NAT1 genotype and cancer.
Deitz
A C
AC
Department of Pharmacology and Toxicology, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota, 58202, USA.
Doll
M A
MA
Hein
D W
DW
D000483:Alleles; D001191:Arylamine N-Acetyltransferase / Q000737:chemistry*; D003106:Colon / Q000737:chemistry; D017931:DNA Primers; D004262:DNA Restriction Enzymes / Q000737:chemistry; D004587:Electrophoresis, Agar Gel; D006801:Humans; D007527:Isoenzymes / Q000737:chemistry*; D008297:Male; D016133:Polymerase Chain Reaction / Q000379:methods; D012150:Polymorphism, Restriction Fragment Length; D011467:Prostate / Q000737:chemistry
D017931:DNA Primers; D007527:Isoenzymes; D001191:Arylamine N-Acetyltransferase; C089384:N-acetyltransferase 1; D004262:DNA Restriction Enzymes